Personalis (PSNL)
(Delayed Data from NSDQ)
$1.21 USD
+0.03 (2.11%)
Updated Jun 27, 2024 04:00 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Brokerage Reports
Personalis, Inc. [PSNL]
Reports for Purchase
Showing records 1 - 20 ( 23 total )
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
NeXT Personal Could Become a New Pillar of Growth; Eyes on ASCO Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Robust Demand for NeXT Personal Dx; Multiple Data Readouts in Mid-2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Clinical Updates of NeXT Personal Could Support Reimbursement Submission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
NeXT Personal Gained Proof-of-Concept in Early Lung Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Collaborations to Aid in Diagnostic Business Growth; New PT $7.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
NeXT Personal Portfolio Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Expect Slow Growth in Biopharma Business; Lower PT to $10; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Diagnostics Business Key for 2023; Aaron Tachibana as Interim CEO to Provide Needed Continuity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Near-Term Headwind to Biopharma Business; Lower PT to $13; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Biopharma Momentum Continues; Eyes on Clinical Diagnostics, Lower PT $26; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Expect Return to Growth in 2H22 Despite Headwinds; Lower PT to $30; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Biopharma Continues to Deliver; VA MVP to Back-Burner; Lower PT to $38; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Biopharma to drive growth in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Hiccup in Population Sequencing Business Likely Transitory; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Expect Biopharma Business to Bloom; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Strong Growth Momentum Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Opportunity in Companion Diagnostics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Expect Growth Momentum to Continue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Personalis, Inc.
Industry: Medical - Generic Drugs
Broader Adoption of NeXT Bodes Well for 2021 and Beyond; Higher $50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S